Topic

Articles

The companies have entered into a development and manufacturing agreement for Anthos Therapeutics’ abelacimab for treating thrombotic disorders.

Lonza, Anthos Therapeutics Partner on Anti-coagulant Biologic Abelacimab

Tabrecta is approved to specifically target metastatic non-small cell lung cancer with a mutation that leads to MET exon 14 skipping (METex14).

FDA Approves Novartis Lung Cancer Drug, Tabrecta

The partnership, led by Takeda and CSL Behring, will focus on developing a hyperimmune immunoglobulin against COVID-19.

Global Plasma Providers Partner to Develop Potential COVID-19 Hyperimmune Therapy

The therapy works by transferring pathogen-specific antibodies from plasma gathered from recovered individuals into an infected patient, which may help the patient’s immune system respond and increase recovery.

Takeda to Develop Plasma-Derived Therapy for COVID-19 Treatment

The agreement centers around the development of new stem-cell derived allogeneic T-cell therapies for the treatment of cancer.

Astellas, Adaptimmune Form Cell Therapy Pact Worth Up to $897.5 million

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Several factors must be considered when reformulating APIs for pediatric, geriatric, and other specialty patient populations.

Adapting APIs for Specialty Dosage Forms

Under a collaboration potentially worth more than $1.5 billion, the companies aim to develop the antisense therapy to treat patients with certain cardiovascular and metabolic diseases.

Pfizer, Akcea Partner for New Antisense Therapy in Deal Potentially Worth $1.5 Billion

Data showed that the drug candidate activated T regulatory cells, believed to serve a crucial role in protecting the body from uncontrolled inflammation or autoimmunity.

Regen Shows Positive Data for CBD Arthritis Treatment

FDA has approved Novo Nordisk’s Rybelsus (semaglutide), a glucagon-like peptide receptor protein treatment in oral tablet form for type 2 diabetes.

FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of AstraZeneca’s Qtrilmet (metformin hydrochloride, saxagliptin, and dapagliflozin) modified-release tablets for treating type-2 diabetes.

Therapeutic-Specific Areas